First Shoulder Arthroplasty Surgeries Using Stryker’s Blueprint® Mixed Reality Guidance System Completed in Europe

Blueprint Mixed Reality Guidance System offers shoulder arthroplasty surgeons a new tool to execute their pre-operative plan

Blueprint Mixed Reality (MR) Guidance

Stryker (NYSE:SYK), a global leader in medical technologies, today announced that the first shoulder arthroplasty surgeries using Blueprint Mixed Reality (MR) Guidance in Europe have been successfully completed by Professor Julien Berhouet, MD, PhD, CHRU Tours Hospital, France, and Dr. Lionel Neyton, MD, orthopaedic shoulder surgeon at Centre Orthopédique Santy and Hôpital Privé Jean Mermoz in Lyon, France.

Professor Berhouet Comments

“It’s exciting to be one of the first two hospitals in Europe to use Stryker’s Mixed Reality Guidance System,” said Professor Berhouet. “I am also pleased to be leading a pilot study to investigate the safety and effectiveness of this new technology, alongside three other centres in France.”

Dr. Lionel Neyton Added

“The Blueprint Mixed Reality System allows me to tailor my shoulder joint replacement procedures to the unique needs and anatomy of my patients,” Dr. Neyton added.

Designed in collaboration with a team of world-class surgeons, the Blueprint Mixed Reality Guidance System combines Stryker’s innovative software with the Microsoft HoloLens 2 headset, allowing the surgeon to track the position and orientation of surgical instrumentation in the physical environment. Blueprint Mixed Reality Guidance System allows surgeons and their instruments to be ‘guided’ by 3D images and guidance widgets, which can be displayed on the patient and in the surgeon’s line of sight without disrupting normal workflow. The MR Guidance system received a CE mark at the end of 2023 and the first surgeries globally were performed in the U.S. and Canada in December 2023.

Markus Ochs, VP and General Manager of Stryker’s European Trauma & Extremities Division

“This latest tool builds upon a decade of Blueprint’s presence in Europe, and we continue innovating to ensure the platform has the potential to further benefit surgeons and patients alike.”

To learn more about Blueprint and Mixed Reality, visit stryker.com.

SourceStryker

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version